Stress response inhibits the nephrotoxicity of cisplatin

American Journal of Physiology - Renal Physiology

Volumn 288, Issue 1 57-1, 2005, Pages

  Hanigan, Marie H ^a,c   Deng, Mei ^b   Zhang, Lei ^a   Taylor, Peyton T ^b   Lapus, Maia G ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Biomedical Research Center   (United States)

Author keywords

cis diamminedichloroplatinum; Kidney; LLC PK 1 cells; Proximal tubule; Toxicity

Indexed keywords

CISPLATIN; SODIUM CHLORIDE;

ANIMAL MODEL; ARTICLE; BIOACCUMULATION; BIOASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; HYDRATION; IN VITRO STUDY; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; STRESS; TISSUE CULTURE;

EID: 11144290019     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00041.2003     Document Type: Article

References (38)

1. Andrews PA. Cisplatin accumulation. In: Platinum-Based Drugs in Cancer Therapy, edited by Kelland LR and Farrell NP. Totowa, NJ: Humana, 2000, p. 89-113.
2. Bajorin D, Bosl GJ, and Fein R. Phase-I trial of escalating doses of cisplatin in hypertonic saline. J Clin Oncol 5: 1589-1593, 1987.
3. Choi JY, Shah M, Lee MG, Schultheis PJ, Shull GE, Muallem S, and Baum M. Novel amiloride-sensitive sodium-dependent proton secretion in the mouse proximal convoluted tubule. J Clin Invest 105: 1141-1146, 2000.
4. Cornelison TL and Reed E. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol 50: 147-158, 1993.
5. Daley-Yates PT and McBrien DCH. A study of the protective effect of chloride salts on cisplatin nephrotoxicity. Biochem Pharmacol 34: 2363-2369, 1985.
6. DeConti RC, Toftness BR, Lange RC, and Creasey WA. Clinical and pharmacological studies with cis-diamminedichloroplatinum (II). Cancer Res 33: 1310-1315, 1973.
7. Dekant W, Vamvakas S, and Anders MW. Formation and fate of nephrotoxic and cytotoxic glutathione S-conjugates: cysteine conjugate β-lyase pathway. In: Advances in Pharmacology, Vol. 27, edited by Anders MW and Dekant W. New York: Academic, 1995, p. 115-162.
8. Dobyan DC, Levi J, Jacobs C, Kosek J, and Weiner MW. Mechanism of cis-platinum nephrotoxicity. II. morphological observations. J Pharmacol Exp Ther 213: 551-556, 1980.
9. Dumas M, de Gislain C, d'Athis P, Chadoint-Noudeau V, Escousse A, Guerrin J, and Autissier N. Influence of hydration on ultrafilterable platinum kinetic and kidney function on patients treated with cis-diamminedichloroplatinum (II). Cancer Chemother Pharmacol 26: 278-282, 1990.
10. Earhart RH, Martin PA, Tutsch KD, Erturk E, Wheeler RH, and Bull FE. Improvement in the therapeutic index of cisplatin (NSC 119875) by pharmacologically induced chloruresis in the rat. Cancer Res 43: 1187-1194, 1983.
11. Einhorn LH. Curing metastatic testicular cancer. Proc Natl Acad Sci USA 99: 4592-4595, 2002.
12. Filipovic D and Sackin H. Stretch- and volume-activated channels in isolated proximal tubule cells. Am J Physiol Renal Fluid Electrolyte Physiol 262: F857-F870, 1992.
13. Finley PR, Grady HJ, Olsowka ES, and Tilzer LL. Chemistry. In: Laboratory Test Handbook, edited by Jacobs DS, DeMott WR, Finley PR, Horvat RT, Kasten BL, and Tilzer LL. Hudson, OH: Lexi-Comp, 1993, p. 94-350.
14. Hanigan MH, Gallagher BC, Taylor PT Jr, and Large MK. Inhibition of γ-glutamyl transpeptidase activity by acivicin in vivo protects the kidney from cisplatin-induced toxicity. Cancer Res 54: 5925-5929, 1994.
15. Hanigan MH, Lykissa ED, Townsend DM, Ou CN, Barrios R, and Lieberman MW. γ-Glutamyl transpeptidase-deficient mice are resistant to the nephrotoxic effects of cisplatin. Am J Pathol 159: 1889-1894, 2001.
16. Hanigan MH and Pitot HC. Isolation of γ-glutamyl transpeptidase positive hepatocytes during the early stages of hepatocarcinogenesis in the rat. Carcinogenesis 3: 1349-1354, 1982.
17. Ishida S, Lee J, Thiele DJ, and Herskowitz I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA 99: 14298-14302, 2002.
18. Kruidering M, van de WB, Zhan Y, Baelde JJ, Heer E, Mulder GJ, Stevens JL, and Nagelkerke JF. Cisplatin effects on F-actin and matrix proteins precede renal tubular cell detachment and apoptosis in vitro. Cell Death Differ 5: 601-614, 1998.
19. Lee J, Pena MM, Nose Y, and Thiele DJ. Biochemical characterization of the human copper transporter Ctr1. J Biol Chem 277: 4380-4387, 2002.
20. Lin X, Okuda T, Holzer A, and Howell SB. The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. Mol Pharmacol 62: 1154-1159, 2002.
21. Litterst CL. Alterations in the toxicity of cis-dichlorodiammineplatinum- II and in tissue localization of platinum as a function of NaCl concentration in the vehicle of administration. Toxicol Appl Pharmacol 61: 99-108, 1981.
22. McKeage MJ, Abel G, Kelland LR, and Harrap KR. Mechanism of action of an orally administered platinum complex [ammine bis butyrato cyclohexylamine dichloroplatinum (IV) (JM221)] in intrinsically cisplatin-resistant human ovarian carcinoma in vitro. Br J Cancer 69: 1-7, 1994.
23. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
24. Ogilvie GK, Krawiec DR, Gelberg HB, Twardock AR, Reschke RW, and Richardson BC. Evaluation of a short-term saline diuresis protocol for the administration of cisplatin. Am J Vet Res 49: 1076-1078, 1988.
25. Okada Y, Maeno E, Shimizu T, Dezaki K, Wang J, and Morishima S. Receptor-mediated control of regulatory volume decrease (RVD) and apoptotic volume decrease (AVD). J Physiol 532: 3-16, 2001.
26. 1. Implication of the functions of apical membranes. Biochem Pharmacol 59: 195-201, 2000.
27. Oleinick NL, Chiu SM, Ramakrishnan N, and Xue LY. The formation, identification, and significance of DNA-protein cross-links in mammalian cells. Br J Cancer Suppl 8: 135-140, 1987.
28. Ozols RF, Corden BJ, Jacob J, Wesley MN, Ostchega Y, and Young RC. High-dose cisplatin in hypertonic saline. Ann Intern Med 100: 19-24, 1984.
29. Pinzani V, Bressolle F, Haug IJ, Galtier M, and Blayac JP. Cisplatin induced renal toxicity and toxicity-modulating strategies: a review. Cancer Chemother Pharmacol 35: 1-9, 1994.
30. Proft M and Struhl K. MAP kinase-mediated stress relief that precedes and regulates the timing of transcriptional induction. Cell 118: 351-361, 2004.
31. Sabra R and Branch RA. Role of sodium in protection by extended-spectrum penicillins against tobramycin-induced nephrotoxicity. Antimicrob Agents Chemother 34: 1020-1025, 1990.
32. Terada Y, Inoshita S, Hanada S, Shimamura H, Kuwahara M, Ogawa W, Kasuga M, Sasaki S, and Marumo F. Hyperosmolality activates Akt and regulates apoptosis in renal tubular cells. Kidney Int 60: 553-567, 2001.
33. Townsend DM, Deng M, Zhang L, Lapus MG, and Hanigan MH. Metabolism of cisplatin to a nephrotoxin in proximal tubule cells. J Am Soc Nephrol 14: 1-10, 2003.
34. Townsend DM and Hanigan MH. Inhibition of γ-glutamyl transpeptidase or cysteine S-conjugate β-lyase activity blocks the nephrotoxicity of cisplatin in mice. J Pharmacol Exp Ther 300: 142-148, 2002.
35. Vermeulen NP, Baldew GS, Los G, McVie JG, and De Goeij JJ. Reduction of cisplatin nephrotoxicity by sodium selenite. Lack of interaction at the pharmacokinetic level of both compounds. Drug Metab Dispos 21: 30-36, 1993.
36. Wachsberger PR, Landry J, Storck C, Davis K, O'Hara MD, Owen CS, Leeper DB, and Coss RA. Mammalian cells adapted to growth at pH 6.7 have elevated HSP27 levels and are resistant to cisplatin. Int J Hyperthermia 13: 251-255, 1997.
37. + exchanger. Am J Physiol Renal Physiol 284: F829-F839, 2003.
38. Zhan Y, van de Water B, Wang Y, and Stevens JL. The roles of caspase-3 and bcl-2 in chemically-induced apoptosis but not necrosis of renal epithelial cells. Oncogene 18: 6505-6512, 1999.